[go: up one dir, main page]

WO2006085910A3 - Endotoxin-free moraxella catarrhalis - Google Patents

Endotoxin-free moraxella catarrhalis Download PDF

Info

Publication number
WO2006085910A3
WO2006085910A3 PCT/US2005/019479 US2005019479W WO2006085910A3 WO 2006085910 A3 WO2006085910 A3 WO 2006085910A3 US 2005019479 W US2005019479 W US 2005019479W WO 2006085910 A3 WO2006085910 A3 WO 2006085910A3
Authority
WO
WIPO (PCT)
Prior art keywords
moraxella catarrhalis
endotoxin
free
lipooligosaccharide
endotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/019479
Other languages
French (fr)
Other versions
WO2006085910A2 (en
Inventor
Xin-Xing Gu
Daxin Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2006085910A2 publication Critical patent/WO2006085910A2/en
Publication of WO2006085910A3 publication Critical patent/WO2006085910A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01129—Acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase (2.3.1.129)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to a Moraxella catarrhalis bacterium comprising a mutation such that it is viable, and lacks endotoxic lipooligosaccharide (LOS), and related vaccines and methods of immunization.
PCT/US2005/019479 2004-06-04 2005-06-03 Endotoxin-free moraxella catarrhalis Ceased WO2006085910A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57724404P 2004-06-04 2004-06-04
US60/577,244 2004-06-04
US61313904P 2004-09-23 2004-09-23
US60/613,139 2004-09-23

Publications (2)

Publication Number Publication Date
WO2006085910A2 WO2006085910A2 (en) 2006-08-17
WO2006085910A3 true WO2006085910A3 (en) 2006-09-28

Family

ID=36662325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019479 Ceased WO2006085910A2 (en) 2004-06-04 2005-06-03 Endotoxin-free moraxella catarrhalis

Country Status (1)

Country Link
WO (1) WO2006085910A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053851A1 (en) * 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
WO1999010497A1 (en) * 1997-08-21 1999-03-04 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
WO1999036086A1 (en) * 1998-01-13 1999-07-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053851A1 (en) * 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
WO1999010497A1 (en) * 1997-08-21 1999-03-04 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
WO1999036086A1 (en) * 1998-01-13 1999-07-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GORTER ANNELIES D ET AL: "Involvement of lipooligosaccharides of Haemophilus influenzae and Neisseria meningitidis in defensin-enhanced bacterial adherence to epithelial cells.", MICROBIAL PATHOGENESIS, vol. 34, no. 3, March 2003 (2003-03-01), pages 121 - 130, XP002392433, ISSN: 0882-4010 *
GU X X ET AL: "Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 5, May 1998 (1998-05-01), pages 1891 - 1897, XP002102901, ISSN: 0019-9567 *
LEY VAN DER P ET AL: "MODIFICATION OF LIPID A BIOSYNTHESIS IN NEISSERIA MENINGITIDIS IPXLMUTANTS: INFLUENCE ON LIPOPOLYSACCHARIDE STRUCTURE, TOXICITY AND ADJUVANT ACTIVITY", INFECTION AND IMMUNITY, AMERICAN SOCIETY OF MICROBIOLOGY, WASHINGTON, DC, US, vol. 69, no. 10, October 2001 (2001-10-01), pages 5981 - 5990, XP001055221, ISSN: 0019-9567 *
LUKE NICOLE R ET AL: "Identification of a 3-deoxy-D-manno-octulosonic acid biosynthetic operon in Moraxella catarrhalis and analysis of a KdsA-deficient isogenic mutant.", INFECTION AND IMMUNITY, vol. 71, no. 11, November 2003 (2003-11-01), pages 6426 - 6434, XP002392434, ISSN: 0019-9567 *
PENG DAXIN ET AL: "Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate", INFECTION AND IMMUNITY, vol. 73, no. 11, November 2005 (2005-11-01), pages 7569 - 7577, XP002392435, ISSN: 0019-9567 *
STEEGHS L ET AL: "Isolation and characterization of the Neisseria meningitidis lpxD-fabZ-lpxA gene cluster involved in lipid A biosynthesis", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 190, no. 2, 1997, pages 263 - 270, XP004116090, ISSN: 0378-1119 *
STEEGHS L ET AL: "Meningitis bacterium is viable without endotoxin", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 392, no. 6675, 2 April 1998 (1998-04-02), pages 449 - 450, XP002338028, ISSN: 0028-0836 *
VAN DER LEY PETER ET AL: "Lessons from an LPS-deficient Neisseria meningitidis mutant.", JOURNAL OF ENDOTOXIN RESEARCH, vol. 9, no. 2, 2003, pages 124 - 128, XP009069936, ISSN: 0968-0519 *

Also Published As

Publication number Publication date
WO2006085910A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
WO2005004909A3 (en) Method of enhanced immunogenicity to meningococcal vaccination
WO2004075829A3 (en) Adjuvanted influenza vaccine
DK1635863T3 (en) Compositions for triggering, enhancing and maintaining immune responses to MHC class-I restricted epitopes for prophylactic or therapeutic purposes
FR2906724B1 (en) METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
EP1594560A4 (en) COMPOSITIONS, METHODS AND KITS ENHANCING THE IMMUNOGENECITY OF A BACTERIAL VACCINE VECTOR
EP2275448A3 (en) Monovalent antibody fragments useful as therapeutics
WO2007103572A3 (en) Extracorporeal removal of microvesicular particles
WO2007100699A3 (en) Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
WO2004087007A3 (en) Hydrogel string medical device
WO2006044857A3 (en) Vaccines against japanese encephalitis virus and west nile virus
NO20072256L (en) New foam modifier, foam made from this foam modifier and a process for making these foams
WO2005037223A3 (en) Methods and compositions for immunomodulation
WO2002080648A3 (en) Mucosal boosting following parenteral priming
WO2003066094A3 (en) Hepatitis b vaccines
ATE414045T1 (en) METHOD FOR PRODUCING FOAM GLASS GRANULES
WO2003051288A3 (en) Mycobacterial vaccine
WO2006085910A3 (en) Endotoxin-free moraxella catarrhalis
AP2006003530A0 (en) Immunogenic HIV compositions and related methods.
WO2005021033A3 (en) Vaccine
EP1495039A4 (en) NEISSERIA MUTANTS, LIPOOLIGOSACCHARIDES AND IMMUNOGENIC COMPOSITIONS
WO2016044137A3 (en) Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis
WO2005065017A3 (en) Methods of inducing il-10 production
WO2008032158A3 (en) Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase